FDA Clears Pfizer's IBRANCE for Metastatic Breast Cancer Maintenance

The U.S. FDA has granted approval for Pfizer's IBRANCE, in combination with other therapies, for the ongoing treatment of adults with specific types of advanced or metastatic breast cancer. This approval applies to patients who have completed initial induction treatment. The decision was based on positive data from the Phase 3 PATINA clinical trial.